119.60
-0.42%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Vitrolife
Its shares trade on Nasdaq Stockholm under the ticker VITR.ST. It has been listed since 26 June 2001. In the fiscal year to 31 December 2025, it reported revenue of SEK 3.44bn and a net loss of SEK 5.01bn. At that date it held total assets of SEK 11.12bn and shareholders' equity of SEK 7.89bn.
Vitrolife AB engages in the development, manufacture, and sale of products and systems for the preparation, cultivation, and storage of human cells, tissue, and organs. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2001-06-26. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. The company also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The firm is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 26 Jun 2001
- Employees
- 418
- Website
- vitrolife.com ↗
Leadership
Pay as last reported
- Mr. Jon SigurdssonChairman of the Board, since 2015SEK 1.3m
- Mr. Bronwyn O'connorPresident, Chief Executive OfficerSEK 17.4m
- Mr. Par IhrskogChief Financial Officer
- Ms. Helena WennerstromActing Chief Financial Officer
- Mr. Ermanno SironiChief Operating Officer
- Ms. Jessica JonassonChief Human Resources Officer
- Ms. Meishan JinSenior Vice President, General Manager, China
- Ms. Erin SchardtSenior Vice President, General Manager, North America
- Ms. Olivia NatensSenior Vice President - Sales and Marketing
- Mr. Claus BisgaardSenior Vice President - Technologies
- Mr. Ricardo CapellaSenior Vice President - Genetics
- Mr. Rickard EricssonSenior Vice President - Innovation
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 67
- Environment
- 76
- Social
- 65
- Governance
- 61
- Direct emissions (scope 1)
- 742 t
- Energy emissions (scope 2)
- 1,324 t
- Value chain emissions (scope 3)
- 18,503 t
- Women in the workforce
- 60%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Vitrolife AB has several strengths that contribute to its success. Firstly, the company has a strong research and development team, constantly innovating and improving its products. Secondly, Vitrolife AB has established itself as a leader in the field of assisted reproductive technology, making it a trusted and reputable brand in the market. Additionally, the company has a global presence, with a wide distribution network and partnerships with fertility clinics worldwide.
Weaknesses
- Despite its strengths, Vitrolife AB also has a few weaknesses that it needs to address. One of the major weaknesses is the high dependence on a few key customers, which can pose a risk to the company's revenue if any of these customers are lost. Another weakness is the limited product portfolio, which makes the company vulnerable to competition and may limit its growth potential. Additionally, the company's heavy reliance on third-party suppliers for raw materials and components may lead to supply chain vulnerabilities.
Opportunities
- There are several opportunities that Vitrolife AB can explore to further strengthen its position in the market. One such opportunity is the growing demand for assisted reproductive technology globally, driven by factors such as increasing infertility rates and changing lifestyles. Expanding into emerging markets, where the adoption of assisted reproductive technology is still in its early stages, could also present significant growth opportunities for the company. Moreover, strategic collaborations and partnerships with fertility clinics and research institutions can help Vitrolife AB stay at the forefront of technological advancements.
Threats
- Vitrolife AB faces several threats in its operating environment that it needs to be aware of. One of the major threats is intense competition from both established players and new entrants in the industry. This competition may result in pricing pressures and reduced market share. Additionally, regulatory challenges, particularly in different countries and regions, can pose risks to the company's operations and product approvals. Economic downturns and fluctuations can also impact the demand for assisted reproductive technology, potentially affecting Vitrolife AB's revenue and profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.